University Hospital, Basel, Switzerland psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University Hospital, Basel, Switzerland is listed with 48 registered studies counted here, in Basel, Switzerland. By compound: 13 psilocybin, 21 MDMA, 25 LSD, 7 DMT, 1 5-MeO-DMT and 2 mescaline. By registry status: 10 recruiting, 2 not yet recruiting and 36 completed. By phase: 7 early phase 1, 28 phase 1, 5 phase 2 and 8 not applicable. Reported start years run from 2009 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 48 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 13 |
| MDMA | 21 |
| LSD | 25 |
| DMT | 7 |
| 5-MeO-DMT | 1 |
| Mescaline | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 10 | 21% |
| Not yet recruiting | 2 | 4% |
| Completed | 36 | 75% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 7 | 15% |
| Phase 1 | 28 | 58% |
| Phase 2 | 5 | 10% |
| Not applicable | 8 | 17% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls | NCT07555132 | Not yet recruiting | Not applicable | 2026-06-01 | MDMA |
| Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants | NCT07444788 | Recruiting | Phase 1 | 2026-03-31 | DMT, 5-MeO-DMT |
| Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants | NCT07494214 | Recruiting | Phase 1 | 2026-03-09 | MDMA |
| Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD | NCT07309471 | Recruiting | Not applicable | 2026-01-01 | LSD |
| Microdosing LSD in Women With Premenstrual Disorders | NCT07189299 | Not yet recruiting | Not applicable | 2025-10-01 | LSD |
| Antidepressant Response of DMT Masked With Propofol | NCT06927076 | Recruiting | Not applicable | 2025-08-05 | LSD, DMT |
| Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants | NCT06905652 | Completed | Phase 1 | 2025-07-29 | MDMA |
| Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness | NCT06796361 | Recruiting | Phase 1 | 2025-04-21 | Psilocybin |
| Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | NCT06884514 | Completed | Phase 1 | 2025-04-03 | Psilocybin, MDMA, LSD |
| Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants | NCT06899334 | Recruiting | Phase 1 | 2025-04-01 | Psilocybin, LSD, DMT |
| Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls | NCT06789705 | Recruiting | Not applicable | 2025-01-27 | MDMA |
| Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants | NCT06180759 | Completed | Phase 1 | 2025-01-23 | Psilocybin, LSD, DMT |
| Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) | NCT05695495 | Completed | Phase 1 | 2024-06-12 | Psilocybin, DMT |
| Lysergic Acid Diethylamide (LSD) in Palliative Care | NCT05883540 | Recruiting | Phase 2 | 2024-06-09 | Psilocybin, LSD |
| LSD Treatment for Persons With Alcohol Use Disorder | NCT05474989 | Recruiting | Phase 2 | 2024-06-01 | LSD |
| LSD-Perceptual-Choice-Study | NCT05976698 | Completed | Not applicable | 2024-02-26 | LSD |
| Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects | NCT05964647 | Completed | Phase 1 | 2024-02-01 | LSD |
| Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose | NCT05809271 | Completed | Phase 1 | 2023-11-17 | MDMA |
| Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects | NCT05523401 | Completed | Phase 1 | 2023-08-16 | Psilocybin, MDMA, LSD |
| Acute Dose-dependent Effects of DMT in Healthy Subjects | NCT05384678 | Completed | Phase 1 | 2022-11-15 | Psilocybin, DMT |
| Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects | NCT05175430 | Completed | Phase 1 | 2022-10-24 | LSD |
| Acute Effects of R- and S-MDMA in Healthy Subjects | NCT05277636 | Completed | Phase 1 | 2022-10-01 | MDMA |
| LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects | NCT04865653 | Completed | Phase 1 | 2022-03-17 | LSD |
| Effects of MDMA-like Substances in Healthy Subjects | NCT04847206 | Completed | Phase 1 | 2021-12-01 | MDMA |
| Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness | NCT04849013 | Completed | Phase 1 | 2021-08-11 | Psilocybin, LSD, Mescaline |
| Effects of Dimethyltryptamine in Healthy Subjects | NCT04353024 | Completed | Phase 1 | 2021-06-18 | LSD, DMT |
| Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls | NCT04648137 | Completed | Not applicable | 2021-02-05 | MDMA |
| Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects | NCT04516902 | Completed | Phase 1 | 2021-01-01 | MDMA, LSD |
| Effect of Ketanserin After LSD Administration | NCT04558294 | Completed | Phase 1 | 2020-10-16 | LSD |
| Comparative Acute Effects of LSD, Psilocybin and Mescaline | NCT04227756 | Completed | Phase 1 | 2020-05-19 | Psilocybin, LSD, Mescaline |
| LSD Therapy for Persons Suffering From Major Depression | NCT03866252 | Completed | Phase 2 | 2019-11-01 | LSD |
| Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction | NCT03527316 | Completed | Early Phase 1 | 2019-10-18 | MDMA |
| Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects | NCT03912974 | Completed | Phase 1 | 2019-07-04 | Psilocybin |
| Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin | NCT03604744 | Completed | Early Phase 1 | 2019-03-27 | Psilocybin, LSD |
| Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache | NCT03781128 | Recruiting | Phase 2 | 2019-01-02 | LSD |
| Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) | NCT03321136 | Completed | Early Phase 1 | 2017-11-28 | LSD |
| LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders | NCT03153579 | Completed | Phase 2 | 2017-06-23 | Psilocybin, LSD |
| Neuronal Correlates of Altered States of Consciousness | NCT02308969 | Completed | Early Phase 1 | 2014-12-01 | LSD |
| Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study | NCT01951508 | Completed | Early Phase 1 | 2013-10-01 | MDMA |
| Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study | NCT01878942 | Completed | Early Phase 1 | 2013-06-01 | LSD |
| Influence of Bupropion on the Effects of MDMA | NCT01771874 | Completed | Phase 1 | 2013-01-01 | MDMA |
| Effects of MDMA and Methylphenidate on Social Cognition | NCT01616407 | Completed | Early Phase 1 | 2012-08-01 | MDMA |
| Emotional Effects of Methylphenidate and MDMA in Healthy Subjects | NCT01465685 | Completed | Phase 1 | 2011-12-01 | MDMA |
| Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) | NCT01386177 | Completed | Phase 1 | 2011-07-01 | MDMA |
| Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA) | NCT01270672 | Completed | Not applicable | 2011-01-01 | MDMA |
| Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) | NCT01136278 | Completed | Phase 1 | 2010-07-01 | MDMA |
| Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) | NCT00990067 | Completed | Phase 1 | 2009-11-01 | MDMA |
| Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK) | NCT00886886 | Completed | Phase 1 | 2009-04-01 | MDMA |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT